Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 19, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 19, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/11/17 - "Examining How Covered Entities Utilize the 340B Drug Pricing Program."
Chairman Murphy, Ranking Member DeGette and Members of the Subcommittee, my name is Charlie Reuland and I am the executive vice president and chief operating officer of The Johns Hopkins Hospital. I. The Johns Hopkins Hospital in Baltimore City, History and Demographics. The bequest left by the philanthropist Johns Hopkins, whose gifts established
10/11/17 - A Deep Dive Into MannKind's Big Bet On Afrezza
It's been a long road for MannKind Corporation and its Afrezza inhalable insulin product. Here's a look at inhalable insulin's long journey and what the new FDA ruling means for MannKind. At the time, MannKind was already working on Afrezza and submitted an NDA to the FDA on March 16, 2009.
10/11/17 - Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
ABO-102 Patients Enrolled in Cohort 3 at 3 E13 vg/kg Accelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underway Day 30 results demonstrate 67% Heparan sulfate reduction in the CNS and 92% reduction in urinary heparan sulfate and normalization of 76% points in liver volume NEW YO
10/11/17 - Absorption Systems Announces Major Expansion of Facilities
By a News Reporter-Staff News Editor at Biotech Week Absorption Systems, a global leader in the advancement of translational medicine, announces a major expansion of two research facilities; near Philadelphia, PA and San Diego, CA. The expansion is driven by sustained demand for the company's high quality contract services to pharmaceutical and..
10/11/17 - Accelerated Path to FDA Approval Subject of Upcoming Panel at CCIT
An alternate path to Food and Drug Administration approval that is gaining popularity will be the focus of a panel discussion on Wednesday, October 18 at the New Jersey Economic Development Authority's Commercialization Center for Innovative Technologies in North Brunswick. Known as the 505 new drug application, this approach to pursuing FDA approv
10/11/17 - Acura Pharmaceuticals Advances LTX - 03 and its LIMITx Technology
Release date- 10102017- PALATINE, Ill.- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-300 for its LIMITx oral abuse deterrent drug LTX-03 demonstrated rapid release of drug from the micro-particle formulation providing expected...
10/11/17 - Adamas Appoints Mardi C. Dier to its Board of Directors
Adamas Pharmaceuticals, Inc. today announced the appointment of Mardi C. Dier, Chief Financial Officer of Portola Pharmaceuticals, Inc., to its Board of Directors. First, I would like to thank Richard for his years of service to Adamas, during which time we brought Adamas public, financed GOCOVRI? through FDA approval and launch, as well as
10/11/17 - Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team
Release date- 10102017- IRVINE, Calif.- Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first in class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of 11 employees to its Research and Development team located
10/11/17 - After 'Brazen' Drug Company Move, McCaskill Takes Action to Protect Consumers With Bill Aimed at Ending Such Deals
Claire McCaskill, D- Mo., issued the following news release:. In a recent deal, Allergan transferred patents on Restasis, a blockbuster eye medicine, to the Saint Regis Mohawk Tribe, which has now used tribal sovereignty to argue that the patents should not be subject to challenge at the U.S. Patent and Trademark Office. Earlier this week McCaskill
10/11/17 - Akari Therapeutics Announces Further Clinical Progress
Akari Therapeutics, Plc, a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, announces that three additional patients have been enrolled in the ongoing Phase II COBALT clinica
10/11/17 - Akcea Therapeutics Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS) [Syrian Arab News Agency]
Akcea Therapeutics UK, the UK subsidiary of Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals, Inc., is focused on developing and commercialising drugs to treat patients with serious cardiometabolic lipid disorders. This designation demonstrates the potential to address clear unmet medical needs in the treatment of this debilitating...
10/11/17 - Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference
Allergan, a leading global pharmaceutical company, announced today that it will present 22 abstracts at the 2017 Fall Clinical Dermatology Conference in Las Vegas from October 12-15. Among the highlights are new presentations on acne and ongoing redness associated with rosacea, containing efficacy data on ACZONE Gel, 7.5% and RHOFADE CREAM,
10/11/17 - Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago
Release date- 10102017- DUBLIN.- Allergan plc, a leading global pharmaceutical company, today announced several Allergan-supported abstracts were selected for poster presentation at the Annual American Academy of Optometry in Chicago, Illinois from October 11- 14, 2017. Date and Time: Friday, October 13 10:00 am- 12:00 pm CT. Authors: D. Evans, S.
10/11/17 - Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
By a News Reporter-Staff News Editor at Biotech Week Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the products.
10/11/17 - Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
Release date- 10102017- SAN DIEGO- Amplyx Pharmaceuticals a company developing novel antimicrobial agents for life threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001, plus new nonclinical data highlighting its breadth of spectrum, at IDWeek 2017 held in San Diego, CA.. APX001 is a broad-spect
10/11/17 - Antihistamine shown to improve function in MS patients
Researchers from the University of California, San Francisco, completed the clinical trial of the U.S. Food and Drug Administration- approved antihistamine clemastine fumarate on patients with MS. The study, published Tuesday in The Lancet, was the first to show a drug is capable of reliably restoring brain function damaged by a neurological diseas
10/11/17 - AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
Release date- 10102017- LOUISVILLE, Colo.- AntriaBio, Inc., a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to its Board of Directors where he will serve as Chairman of the Audit Committee. Mr. Labrucherie is currently S
10/11/17 - Aravive Biologics Named as One of FierceBiotech's "Fierce 15" Biotech Companies of 2017
By a News Reporter-Staff News Editor at Biotech Week Aravive Biologics, Inc. announced that it has been named by FierceBiotech as one of 2017' s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. "We are honored to be selected to the" Fierce 15 "class of 2017," said Ste
10/11/17 - Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017
Release date- 10102017- WALTHAM, Mass. and VIENNA, Austria- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company presented pharmacokinetic data from a Phase 1 clinical trial in healthy volunteers and from a preclinic
10/11/17 - AstraZeneca - The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer
Release date- 10102017- AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced that the European Medicines Agency has accepted a Marketing Authorisation Application for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer whose disease has not progressed...
10/11/17 - At 10.8 % CAGR, Global Generic Drug Market Size & Share Will Reach $380.60 Billion by 2021: Zion Market Research
Zion Market Research has published a new report titled Generic Drug Market by Brand for Central Nervous System, Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications- Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 2021. According to the report, the global generic drug market accoun
10/11/17 - Bioasis Establishes U.S. Presence with Office in Connecticut [Sport360]
BIOASIS TECHNOLOGIES INC., a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the central nervous system for the treatment of neurological diseases and disorders, today announced the establishment of its U.S. office in Guilford, Conn. Additionally, the Company has launched its new corporate w
10/11/17 - Biocon gets complete response letter from US drug authority for anti-cancer drug [Arab Times (Kuwait)]
Biotechnology firm Biocon on Tuesday said the United States health regulator has issued complete response letter for proposed biosimilar Pegfilgrastim, indicated for use in cancer treatment. The company, however said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the U.S. This product is a part of
10/11/17 - BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
BioMarin Pharmaceutical Inc. will host an R&D Day from 8 am to 1 pm on Wednesday, October 18, 2017 in New York City. BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. Maureen Cleary, M.D.,
10/11/17 - BIOPHYTIS completes a ?10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates
BIOPHYTIS, a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announces entry into definitive agreements for a? 10.4 million capital raise via the issuance of new ordinary shares without shareholders preferential subscription rights and reserved to institutional investors in Europe and t
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement